Tanvex BioPharma (TPE:6541) Margin of Safety % (DCF FCF Based): N/A (As of Jul. 05, 2026)


TPE:6541 Tanvex BioPharma Inc TPE:6541
57 GF Score
Price NT$41.40
GF Value NT$254.61
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Tanvex BioPharma Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Tanvex BioPharma's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

TPE:6541 vs VRTX, REGN, ALNY: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Tanvex BioPharma's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tanvex BioPharma Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tanvex BioPharma's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Tanvex BioPharma's Margin of Safety % (DCF FCF Based) falls into.


TPE:6541
57GF Score
Tanvex BioPharma Inc TPE:6541
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Tanvex BioPharma (TPE:6541) Overvalued in 2026?

Based on GuruFocus' analysis, Tanvex BioPharma stock appears to be undervalued. The current stock price of NT$41.40 is trading 83.7% below its estimated GF Value™ of NT$254.61. GuruFocus considers Tanvex BioPharma to be Possible Value Trap.

Key valuation signals for TPE:6541:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: NT$254.61 vs. price of NT$41.40 (83.7% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the TPE:6541 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tanvex BioPharma Business Description

Address No. 12-2, Shengyi Road, Section 2, 6th Floor, Hsinchu County, Zhubei, TWN, 106
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.
57GF Score

Get the complete analysis for TPE:6541

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$41.40
Price
NT$254.61
GF Value